Rezolve AI arrives at Tuesday's October 6 print with short sellers still deeply committed and the borrow market tightening again, even as the stock slides to $2.06.
The lending picture has shifted noticeably in just the past week. Availability has dropped to 16%, down from 29% a week ago, a move of nearly 45%, meaning roughly one share remains available to borrow for every six already lent out. That is the tightest availability reading in several weeks, and it accompanies a cost to borrow that, while down from its September 9 peak of 71.8%, still runs at 18.5%. Shorts who held through that borrow spike have been rewarded with a stock now 14% lower than a month ago. Short interest itself has eased fractionally from the 16% peak hit in mid-September, but at 13.8% of free float it remains structurally elevated: the ORTEX short score of 78.6 ranks in the second percentile of the universe, a signal of intense bearish conviction. Options positioning, by contrast, is not particularly defensive. The put/call ratio of 0.25 sits only modestly above its 20-day average, suggesting that options traders are not piling into downside protection ahead of the print.
The debate going into Tuesday is not really about near-term revenue. Management affirmed FY2026 guidance of $360 million on September 1 and announced a $60 million annualised cost-reduction programme shortly after, with a stated path to positive adjusted EBITDA as the company exits H1 2027. Bulls argue those two pieces, a revenue ambition and a credible cost structure, are enough to justify the stock at current levels. Bears are less convinced: the ORTEX stock score's Value and Quality pillars remain deeply depressed, the company is loss-making on a trailing basis, and the EV/EBITDA multiple is deeply negative, reflecting how far Rezolve has to travel before the profitability promise becomes a fact. Daniel Wagner, the CEO, holds a 13D-disclosed activist stake of 13.8% as last filed on August 28, a decline from 15.6% previously, but he also made open-market purchases at $4.00 per share in April, well above the current price. That buying is a data point, though it predates the stock's further decline to $2.06. As always with Schedule 13D/G disclosures, stakes are as last reported and positions can change without a further filing.
Peer performance adds another layer of discomfort for bulls. AISP gained nearly 20% on Thursday alone and REKR added 3.7%, while RZLV fell 3.3% on the same session. The stock's recent notes flagged this divergence: peers like PLTR have participated in the broader AI bid while Rezolve has not. The last earnings event, in early September, resulted in a one-day decline of 19.4% and a five-day loss of 20.1%. That reaction set the baseline for what a disappointing print can do to a stock already under heavy short pressure with tight availability.
The October 6 print will test whether management's two-part story, aggressive revenue guidance paired with a fresh cost-discipline commitment, can shift the calculus for a short base that has absorbed considerable borrowing costs without retreating.
See the live data behind this article on ORTEX.
Open RZLV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
